or Try an Advanced Search...

    Technical Analysis for GANX - Gain Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.12 -12.50% -0.16
    GANX closed down 12.5 percent on Monday, July 1, 2024, on 2.27 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GANX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Expansion Breakdown Bearish Swing Setup 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion -12.50%
    Wide Bands Range Expansion -12.50%
    Oversold Stochastic Weakness -12.50%
    Narrow Range Bar Range Contraction -10.40%
    Wide Bands Range Expansion -10.40%
    Older End-of-Day Signals for GANX ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 6 hours ago
    2x Volume Pace about 8 hours ago
    Fell Below Previous Day's Low about 8 hours ago
    1.5x Volume Pace about 8 hours ago
    New 52 Week Low about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GANX Chart by TradingView
    Basic chart:

    Profile

    Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group

    Is GANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Gain Therapeutics, Inc. (GANX) Special Call Transcript
    Jun 28 Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
    Jun 27 Gain Therapeutics names Gene Mack as Interim CEO
    Jun 27 Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
    Jun 27 Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
    Jun 25 Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
    Jun 14 Dow Tumbles Over 200 Points; Adobe Earnings Top Views
    Jun 14 Gain Therapeutics shares slide on pricing public offering of units to raise $11M
    Jun 14 Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
    Jun 13 Gain Therapeutics shares fall on proposed public offering
    See more GANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.33
    52 Week Low 1.11
    Average Volume 272,770
    200-Day Moving Average 3.17
    50-Day Moving Average 2.33
    20-Day Moving Average 1.72
    10-Day Moving Average 1.27
    Average True Range 0.21
    RSI (14) 23.66
    ADX 43.8
    +DI 6.72
    -DI 30.11
    Chandelier Exit (Long, 3 ATRs) 2.25
    Chandelier Exit (Short, 3 ATRs) 1.73
    Upper Bollinger Bands 2.76
    Lower Bollinger Band 0.68
    Percent B (%b) 0.21
    BandWidth 121.05
    MACD Line -0.37
    MACD Signal Line -0.35
    MACD Histogram -0.0153
    Fundamentals Value
    Market Cap 18.14 Million
    Num Shares 16.2 Million
    EPS -1.81
    Price-to-Earnings (P/E) Ratio -0.62
    Price-to-Sales 1400.35
    Price-to-Book 10.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.35
    Resistance 3 (R3) 1.38 1.32 1.31
    Resistance 2 (R2) 1.32 1.26 1.31 1.30
    Resistance 1 (R1) 1.22 1.22 1.19 1.20 1.29
    Pivot Point 1.17 1.17 1.15 1.15 1.17
    Support 1 (S1) 1.07 1.11 1.04 1.04 0.95
    Support 2 (S2) 1.01 1.07 1.00 0.94
    Support 3 (S3) 0.91 1.01 0.93
    Support 4 (S4) 0.89